EAN 2020 | Ongoing reporting supports long-term safety of ocrelizumab in MS

Stephen Hauser reports the ongoing safety data for ocrelizumab in patients with relapsing or primary progressive multiple sclerosis, including preliminary post-marketing experience of a small group of patients with COVID-19 (5:13).